The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
In order to quantify the role of incretins in first- and second-phase insulin secretion (ISR) in type 2 diabetes mellitus (T2DM), a double-blind, randomized study with 12 T2DM subjects and 12 healthy subjects (HS) was conducted using the hyperglycemic clamp technique together with duodenal nutrition perfusion and intravenous infusion of the glucagon-like peptide 1 (GLP-1) receptor antagonist exendin(9-39). Intravenous glucose alone resulted in a significantly greater first- and second-phase ISR in HS compared with T2DM subjects. Duodenal nutrition perfusion augmented both first- and second-phase ISR but first-phase ISR more in T2DM subjects (approximately eight- vs. twofold). Glucose-related stimulation of ISR contributed only 20% to overall ISR. Infusion with exendin(9-39) significantly reduced first- and second-phase ISR in both HS and T2DM subjects. Thus, both GLP-1 and non–GLP-1 incretins contribute to the incretin effect. In conclusion, both phases of ISR are impaired in T2DM. In particular, the responsiveness to glucose in first-phase ISR is blunted. GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) secretions are unaltered. The absolute incretin effect is reduced in T2DM; its relative importance, however, appears to be increased, highlighting its role as an important amplifier of first-phase ISR in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![FIG. 2. Plasma insulin (A and B) and C-peptide (C and D) in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles), exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares), and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A and C) and patients with T2DM (B and D). Blood glucose concentrations are shown in A and B (black and white symbols). n = 12 per group; mean ± SEM. See Tables 2 and 3 for statistical analysis.](https://figures.cochat.ai/paper-figures/244925cfa7d14e80abcd1c9deb0fddde/the-role-of-endogenous-incretin-secretion-as-amplifier-of-glucose-stimulated-figure-2.jpg)
![FIG. 3. Plasma insulin (A and B), incretin effect (C and D), and percentage contribution of the incretin effect to the total insulin response (E and F) in response to hyperglycemic isoglycemic clamp experiments during first-phase ISR (A, C, and E) and second-phase ISR (B, D, and F) with intravenous (IV) isoglycemic glucose experiments without intraduodenal meal perfusion (isoglycemic fasting control, white bars), with saline IV plus duodenal meal (black bars), and with exendin(9-39) (ex[9-39]) IV plus duodenal meal (striated bars) in HS and patients with T2DM. n = 12 per group; mean ± SEM of incremental AUC. *P < 0.05 vs. isoglycemic fasting control; #P < 0.05 vs. saline IV plus duodenal meal. See Tables 2 and 3 for further statistical analysis.](https://figures.cochat.ai/paper-figures/c24be5fff0e042eea89871283d55b4e3/the-role-of-endogenous-incretin-secretion-as-amplifier-of-glucose-stimulated-figure-3.jpg)
![FIG. 4. Plasma GLP-1 (A and B) and GIP (C and D) concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A and C) and patients with T2DM (B and D). n = 12 per group; mean ± SEM. See Table 3 for statistical analysis.](https://figures.cochat.ai/paper-figures/77a4c2721e60476bbc15891105cdcb0c/the-role-of-endogenous-incretin-secretion-as-amplifier-of-glucose-stimulated-figure-4.jpg)
![FIG. 5. Plasma glucagon concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A) and patients with T2DM (B). n = 12 per group; mean ± SEM. See Table 3 for statistical analysis.](https://figures.cochat.ai/paper-figures/4f55c397dcc249b2baeaffd241fad340/the-role-of-endogenous-incretin-secretion-as-amplifier-of-glucose-stimulated-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been demonstrated that the insulin released during the early and late postprandial period by T2D patients is ~25 and 40%, respectively, of that produced by healthy individuals with a similar BMI.107”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fasting insulin levels in T2D patients are ~50% of that observed in healthy subjects with a similar BMI,107”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredIn the citing paper
“demonstrating that T2D has a more significant effect on impairing the insulin response during the postprandial period in the early stages of the disease.”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 5×
“Plasma glucagon concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A…”
InfluentialNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 5×
“Plasma glucagon concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A…”
InfluentialVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Gastric emptying and release of incretin hormones after glucose ingestion in humans.
Schirra, J., Katschinski, M., Weidmann, C., Schäfer, T., Wank, U., Arnold, R., & Göke, B. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118411 · Cited by 426
Self-citationMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 5×
“Plasma glucagon concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A…”
Influential
Research works printed but not linked: 1
- Schirra, 2008, The efficacy of exendin(9-39)amide as a GLP-1 receptor antagonist in human, Gut, 57, A85
Cited by
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Metadata
- Authors
- Woerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J.
- Affiliations
- LMU Klinikum (DE)
- Corresponding author
- Schirra, Jörg
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-08-17
- Volume
- 61
- Issue
- 9
- Pages
- 2349-2358
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3425423
- OpenAlex
- W2029355071
- Cited by
- 73
- References
- 41
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 7 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 8 · 2016: 10 · 2015: 10 · 2014: 13 · 2013: 14 · 2012: 1
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- incretins, glucose-stimulated insulin secretion, type 2 diabetes, first-phase insulin secretion, second-phase insulin secretion, glucagon-like peptide-1, exendin-9-39, glucose-dependent insulinotropic polypeptide, incretin effect, hyperglycemic clamp
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Glucagon, Glucose, Humans, Insulin, Male, Middle Aged, Peptide Fragments, Glucose Clamp Technique, Receptors, Glucagon, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/db11-1701
- The paper
- Woerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012). The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db11-1701
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.